3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
13
Phase 1
3
Phase NA
2
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma
7
Lymphoma, Follicular
6
Leukemia, Biphenotypic, Acute
6
Leukemia
6
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Large-Cell, Immunoblastic
3
Leukemia, Myeloid, Acute
3
Burkitt Lymphoma
3
Prostatic Neoplasms
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Multiple Myeloma
2
Lymphohistiocytosis, Hemophagocytic
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Graft vs Host Disease
2
Epstein-Barr Virus Infections
2
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia, Pneumocystis
1
Pneumonia
1
Pain
1
Neurotoxicity Syndromes
1
Neuroma, Acoustic
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Lymphoma, Large-Cell, Anaplastic
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Methylprednisolone
×
Clear all
NCT06097364
2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
733 enrolled